Foghorn Therapeutics isn’t having much luck with FHD-286. Only weeks after the FDA released a trial of the drug in two blood cancers from a clinical hold, the biotech has abandoned plans for the candidate in an eye tumor after taking a look at phase 1 data.

Cognition Therapeutics has released data on the effect its Alzheimer’s disease drug candidate had on an exploratory endpoint in a small clinical trial, offering another look at how the molecule acts on the brain as the biotech heads toward more important readouts.

The results of a new study show that it's possible to target the enzyme CaMKII in the heart without affecting it in the brain. They also suggest that ruxolitinib, a JAK1/2 inhibitor commercialized by Novartis as Jakavi, stops arrhythmias in their tracks.

In a surprise decision, the FDA issued powerhouse Eylea's high-dose version a complete response letter. But the company said it has nothing to do with the drug's efficacy or safety.

Retiring from Emergent BioSolutions in 2010 didn’t take for Robert Kramer. He was wooed back to the company a year later and eventually became the contract manufacturer’s president, CEO and a member of its board. Now, Kramer has done it again, announcing his retirement, effective immediately. Kramer will be replaced as CEO on an interim basis by Haywood Miller.

Tandem Diabetes Care’s insulin pumps already make up more than a third of those used by people with Type 1 diabetes in the U.S., according to Elizabeth Gasser, an executive VP at Tandem and its chief strategy officer—but the company wants an even bigger piece of the pie.

Bristol Myers Squibb went big on display ads at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023. That is one of the takeaways of ZoomRx’s analysis of the online activities of oncologists, which showed promotions of Bristol Myers’ cell therapies Abecma and Breyanzi were the most seen ads.